{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:39:37Z","timestamp":1790912377477,"version":"4.1.0"},"reference-count":66,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Respiratory syncytial virus (RSV), COVID-19, and seasonal influenza represent significant health threats to older adults. These pathogens frequently co-circulate during the same seasons. Co-administration of vaccines targeting these viruses is a practical strategy to enhance vaccination coverage and convenience. However, real-world safety data on the simultaneous administration of RSV, COVID-19, and influenza vaccines in adults aged 60 and older remain limited.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>This study aimed to explore the safety profile of co-administration of RSV, COVID-19, and influenza vaccines in adults aged 60 and older. Using data from the U.S. Vaccine Adverse Event Reporting System (VAERS), the study aimed to identify patterns of adverse events following immunization (AEFIs) and generate hypotheses regarding possible safety signals, to guide clinical practice and public health strategies. These findings should be interpreted as hypothesis-generating and require confirmation through robust observational studies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>AEFI reports for individuals aged 60\u00a0years or older were retrieved from VAERS between 3 May 2023, and 1 January 2025. Three study cohorts were established: the RSV\u2013COVID-19 co-administration group, the RSV\u2013seasonal influenza co-administration group, and the triple-vaccination group. Four disproportionality analysis methods were applied\u2014reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS)\u2014to detect potential safety signals.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 479, 576, and 194 AEFI reports were gathered from the RSV\u2013COVID-19, RSV\u2013influenza, and triple-vaccination groups, respectively. Female reporters outnumbered male reporters by a factor of 2\u20133. More than 96% of AEFIs occurred within 30\u00a0days post-vaccination, with considerable variation in the onset time distribution. Non-serious AEFIs accounted for 85.6%\u201388.5%, with the majority of clinical outcomes classified as <jats:italic>recovered<\/jats:italic>. At the System Organ Class (SOC) level, AEFIs were primarily concentrated in general disorders and administration site conditions, as well as nervous system disorders and abnormal laboratory findings. Potential safety signals included ear and labyrinth disorders, skin and subcutaneous tissue disorders, and injury, poisoning, and procedural complications. At the Preferred Term (PT) level, commonly reported AEFIs included headache, fatigue, and injection site pain, while potential safety signals included aphasia, oral mucosal blisters, and gait disturbance. Among serious reports, high-confidence signals such as influenza-like illness, cerebrovascular accidents, and muscular weakness were identified across all groups. Some high-confidence signals, including sleep disorders and contusions, were also observed in non-serious reports.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The overall safety profile of co-administered RSV, COVID-19, and influenza vaccines in older adults is favorable, with most AEFIs being expected and self-limiting. It is crucial to emphasize that this study is hypothesis-generating; the findings do not prove any causal association between vaccines and the reported adverse events. The potential signals of rare but high-risk events, such as neurological, psychiatric, and cardiovascular complications, must be investigated and confirmed in robust observational studies. Enhanced long-term surveillance is recommended to further understand these potential risks.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1682119","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T05:24:12Z","timestamp":1760937852000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Real-world feasibility of co-administration of RSV, COVID-19, and influenza vaccines in older adults: a VAERS-based analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Zhen","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"218","DOI":"10.7774\/cevr.2024.13.3.218","article-title":"Incidence of narcolepsy symptoms after taking COVID-19 vaccines: a Jordanian cross-sectional study","volume":"13","author":"Al Katatbeh","year":"2024","journal-title":"Clin. Exp. Vaccine Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1002\/mus.22077","article-title":"Safety of influenza and H1N1 vaccinations in patients with myasthenia gravis, and patient compliance","volume":"43","author":"Auriel","year":"2011","journal-title":"Muscle Nerve"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2550857","DOI":"10.1080\/21645515.2025.2550857","article-title":"Post-marketing safety monitoring of RSV vaccines: a real-world study based on the vaccine adverse event reporting system (VAERS)","volume":"21","author":"Bao","year":"2025","journal-title":"Hum. Vaccin Immunother."},{"key":"B4","doi-asserted-by":"publisher","first-page":"919","DOI":"10.3122\/jabfm.2012.06.110334","article-title":"A \u201cneedling\u201d problem: shoulder injury related to vaccine administration","volume":"25","author":"Barnes","year":"2012","journal-title":"J. Am. Board Fam. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2195786","DOI":"10.1080\/21645515.2023.2195786","article-title":"Vaccine co-administration in adults: an effective way to improve vaccination coverage","volume":"19","author":"Bonanni","year":"2023","journal-title":"Hum. Vaccin Immunother."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1007\/s40121-024-00985-4","article-title":"Randomized, open-label phase 3 study evaluating immunogenicity, safety, and reactogenicity of RSVPreF3 OA coadministered with FLU-QIV-HD in adults aged \u2265 65","volume":"13","author":"Buynak","year":"2024","journal-title":"Infect. Dis. Ther."},{"key":"B7","unstructured":"Influenza (flu) vaccine safety\n          \n          \n          2024"},{"key":"B8","unstructured":"Safety considerations for COVID-19 vaccines"},{"key":"B9","unstructured":"Respiratory syncytial virus (RSV) vaccine safety"},{"key":"B10","unstructured":"COVID-19 vaccine frequently asked questions"},{"key":"B11","unstructured":"U.S. influenza surveillance: purpose and methods"},{"key":"B12","unstructured":"RSV vaccine guidance for adults"},{"key":"B13","doi-asserted-by":"publisher","first-page":"ciad786","DOI":"10.1093\/cid\/ciad786","article-title":"Immunogenicity, reactogenicity, and safety of AS01E-adjuvanted respiratory syncytial virus (RSV) prefusion F protein-based candidate vaccine (RSVPreF3 OA) when Co-administered with a seasonal quadrivalent influenza vaccine in older adults: results of a phase 3, open-label, randomized controlled trial","author":"Chandler","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1093\/cid\/ciae365","article-title":"Safety and immunogenicity of respiratory syncytial virus prefusion F protein vaccine when Co-administered with adjuvanted seasonal quadrivalent influenza vaccine in older adults: a phase 3 randomized trial","volume":"79","author":"Clark","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1080\/21645515.2015.1017694","article-title":"Best vaccination practice and medically attended injection site events following deltoid intramuscular injection","volume":"11","author":"Cook","year":"2015","journal-title":"Hum. Vaccin Immunother."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1323057","DOI":"10.3389\/fdsfr.2023.1323057","article-title":"Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems","volume":"3","author":"Cutroneo","year":"2023","journal-title":"Front. Drug Saf. Regul."},{"key":"B17","doi-asserted-by":"publisher","first-page":"Jc41","DOI":"10.7326\/annals-25-00904-jc","article-title":"Coadministration of RSV + influenza or COVID-19 vaccines was noninferior to separate administration for immune responses in adults aged \u226550 y","volume":"178","author":"Dacso","year":"2025","journal-title":"Ann. Intern Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1111\/j.1365-2230.2008.02835.x","article-title":"Exacerbation of pemphigus after influenza vaccination","volume":"33","author":"De Simone","year":"2008","journal-title":"Clin. Exp. Dermatology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s40121-024-01079-x","article-title":"The impact of vaccination on COVID-19, influenza, and respiratory syncytial virus-related outcomes: a narrative review","volume":"14","author":"Debbag","year":"2025","journal-title":"Infect. Dis. Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1002\/lary.30395","article-title":"Prevalence of new-onset tinnitus after COVID-19 vaccination with comparison to other vaccinations","volume":"133","author":"Dorney","year":"2023","journal-title":"Laryngoscope"},{"key":"B21","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1093\/brain\/aws129","article-title":"A Bayesian account of 'hysteria","volume":"135","author":"Edwards","year":"2012","journal-title":"Brain"},{"key":"B22","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3390\/vaccines11010109","article-title":"From Co-Administration to Co-formulation: the race for new vaccines against COVID-19 and other respiratory viruses","volume":"11","author":"Focosi","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1073\/pnas.1321060111","article-title":"Systems analysis of sex differences reveals an immunosuppressive role for testosterone in the response to influenza vaccination","volume":"111","author":"Furman","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B24","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","article-title":"The REporting of A disproportionality analysis for DrUg safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): explanation and elaboration","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf."},{"key":"B25","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/s1473-3099(24)00589-9","article-title":"Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial","volume":"25","author":"Goswami","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s40264-024-01433-5","article-title":"Comparators in pharmacovigilance: a quasi-quantification bias analysis","volume":"47","author":"Gravel","year":"2024","journal-title":"Drug Saf."},{"key":"B27","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3390\/vaccines10020233","article-title":"Gender differences in adverse events following the Pfizer-BioNTech COVID-19 vaccine","volume":"10","author":"Green","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B28","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/jth.15572","article-title":"Vaccine-induced immune thrombotic thrombocytopenia (VITT): update on diagnosis and management considering different resources","volume":"20","author":"Greinacher","year":"2022","journal-title":"J. Thromb. Haemost."},{"key":"B29","doi-asserted-by":"publisher","first-page":"685","DOI":"10.15585\/mmwr.mm7018e3","article-title":"Anxiety-related adverse event clusters after janssen COVID-19 vaccination - five U.S. mass vaccination sites, April 2021","volume":"70","author":"Hause","year":"2021","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e2444756","DOI":"10.1001\/jamanetworkopen.2024.44756","article-title":"Burden of respiratory syncytial virus-associated hospitalizations in US adults, October 2016 to September 2023","volume":"7","author":"Havers","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e175401","DOI":"10.1172\/jci.insight.175401","article-title":"Modulation of innate immune response to mRNA vaccination after SARS-CoV-2 infection or sequential vaccination in humans","volume":"9","author":"Hellgren","year":"2024","journal-title":"JCI Insight"},{"key":"B32","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41541-019-0132-6","article-title":"The how's and what's of vaccine reactogenicity","volume":"4","author":"Herv\u00e9","year":"2019","journal-title":"NPJ Vaccines"},{"key":"B33","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41541-023-00702-1","article-title":"Memory-like innate response to booster vaccination with MF-59 adjuvanted influenza vaccine in children","volume":"8","author":"Kazmin","year":"2023","journal-title":"NPJ Vaccines"},{"key":"B34","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/jamaneurol.2021.1042","article-title":"Helping the public understand adverse events associated with COVID-19 vaccinations: lessons learned from functional neurological disorder","volume":"78","author":"Kim","year":"2021","journal-title":"JAMA Neurol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.1038\/s41380-024-02627-0","article-title":"Psychiatric adverse events following COVID-19 vaccination: a population-based cohort study in Seoul, South Korea","volume":"29","author":"Kim","year":"2024","journal-title":"Mol. Psychiatry"},{"key":"B36","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/s1473-3099(10)70049-9","article-title":"The Xs and Y of immune responses to viral vaccines","volume":"10","author":"Klein","year":"2010","journal-title":"Lancet Infect. Dis."},{"key":"B37","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1001\/jama.2024.1059","article-title":"Stroke risk after COVID-19 bivalent vaccination among US older adults","volume":"331","author":"Lu","year":"2024","journal-title":"Jama"},{"key":"B38","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s40121-024-01082-2","article-title":"Respiratory virus vaccines: pathways to recommendations and enhanced coverage for At-Risk populations","volume":"14","author":"Maggi","year":"2025","journal-title":"Infect. Dis. Ther."},{"key":"B39","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s40264-024-01406-8","article-title":"Safety of simultaneous administration of bivalent mRNA COVID-19 and influenza vaccines in the vaccine adverse event reporting system (VAERS)","volume":"47","author":"Moro","year":"2024","journal-title":"Drug Saf."},{"key":"B40","doi-asserted-by":"publisher","first-page":"127497","DOI":"10.1016\/j.vaccine.2025.127497","article-title":"Safety monitoring of Pfizer's respiratory syncytial virus vaccine in pregnant women in the vaccine adverse Event reporting system (VAERS), 2023-2024, United States","volume":"62","author":"Moro","year":"2025","journal-title":"Vaccine"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2327736","DOI":"10.1080\/21645515.2024.2327736","article-title":"No immunological interference or concerns about safety when seasonal quadrivalent influenza vaccine is co-administered with a COVID-19 mRNA-1273 booster vaccine in adults: a randomized trial","volume":"20","author":"Naficy","year":"2024","journal-title":"Hum. Vaccin Immunother."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/s0140-6736(24)01738-0","article-title":"Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-Associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to march, 2024: a test-negative design analysis","volume":"404","author":"Payne","year":"2024","journal-title":"Lancet"},{"key":"B43","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jointm.2024.03.001","article-title":"Severe respiratory syncytial virus disease","volume":"4","author":"Pe\u00f1a-L\u00f3pez","year":"2024","journal-title":"J. Intensive Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.medcle.2021.01.009","article-title":"The impact of influenza vaccination on cardiovascular disease","volume":"157","author":"P\u00e9rez-Rubio","year":"2021","journal-title":"Med. Clin. Engl. Ed."},{"key":"B45","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","article-title":"A guide to vaccinology: from basic principles to new developments","volume":"21","author":"Pollard","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"2253589","DOI":"10.1080\/21645515.2023.2253589","article-title":"Oral adverse events following COVID-19 and influenza vaccination in Australia","volume":"19","author":"Riad","year":"2023","journal-title":"Hum. Vaccin Immunother."},{"key":"B47","doi-asserted-by":"publisher","first-page":"421","DOI":"10.3390\/epidemiologia5030031","article-title":"Occurrence of central nervous system complications of respiratory syncytial virus infections: a systematic review with meta-analysis","volume":"5","author":"Ricc\u00f2","year":"2024","journal-title":"Epidemiol. (Basel)"},{"key":"B48","article-title":"Safety and immunogenicity of RSVPreF3 vaccine coadministered with seasonal influenza vaccine in older adults","author":"Rizkalla","year":"2023","journal-title":"FDA Present. Vaccines Relat. Biol. Prod. Advis. Comm."},{"key":"B49","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/s1473-3099(22)00054-8","article-title":"Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the vaccine adverse event reporting system and v-safe","volume":"22","author":"Rosenblum","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"B50","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"B51","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s40264-025-01547-4","article-title":"Signal monitoring for adverse events following immunisation with COVID-19 vaccines during the SARS-CoV-2 pandemic: an evaluation of the South African surveillance system","volume":"48","author":"Sankar","year":"2025","journal-title":"Drug Saf."},{"key":"B52","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1016\/j.vaccine.2023.03.054","article-title":"Real-life safety profile of mRNA vaccines for COVID-19: an analysis of VAERS database","volume":"41","author":"Santi Laurini","year":"2023","journal-title":"Vaccine"},{"key":"B53","doi-asserted-by":"publisher","first-page":"7961","DOI":"10.1038\/s41467-023-43420-x","article-title":"Interaction dynamics between innate and adaptive immune cells responding to SARS-CoV-2 vaccination in non-human Primates","volume":"14","author":"Schramm","year":"2023","journal-title":"Nat. Commun."},{"key":"B54","doi-asserted-by":"publisher","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the vaccine adverse event reporting system (VAERS)","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine"},{"key":"B55","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/s2213-2600(21)00409-4","article-title":"Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial","volume":"10","author":"Toback","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"702","DOI":"10.3109\/00365548.2011.580777","article-title":"Explorations of clinical trials and pharmacovigilance databases of MF59\u00ae-adjuvanted influenza vaccines for associated cases of narcolepsy","volume":"43","author":"Tsai","year":"2011","journal-title":"Scand. J. Infect. Dis."},{"key":"B57","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/vaccines11010016","article-title":"Combining influenza and COVID-19 booster vaccination strategy to improve vaccination uptake necessary for managing the health pandemic: a systematic review and meta-analysis","volume":"11","author":"Tzenios","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B58","unstructured":"21 CFR 600.80 postmarketing reporting of adverse experiences\n          \n          \n          2014"},{"key":"B59","unstructured":"Flu, COVID-19, and RSV vaccines: common questions and concerns\n          \n          \n          2025"},{"key":"B60","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1001\/jamainternmed.2024.0212","article-title":"Acute cardiac events in hospitalized older adults with respiratory syncytial virus infection","volume":"184","author":"Woodruff","year":"2024","journal-title":"JAMA Intern Med."},{"key":"B61","unstructured":"Respiratory syncytial virus (RSV)\n          \n          \n          2025"},{"key":"B62","doi-asserted-by":"publisher","first-page":"2345505","DOI":"10.1080\/21645515.2024.2345505","article-title":"Association between combination COVID-19-influenza vaccination and long COVID in middle-aged and older Europeans: a cross-sectional study","volume":"20","author":"Wu","year":"2024","journal-title":"Hum. Vaccin Immunother."},{"key":"B63","doi-asserted-by":"publisher","first-page":"350","DOI":"10.46234\/ccdcw2024.066","article-title":"Comparison of statistical signal detection methods in adverse events following immunization - china, 2011-2015","volume":"6","author":"Xia","year":"2024","journal-title":"China CDC Wkly."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1186\/s12879-024-10048-1","article-title":"Comparative study on the epidemiological characteristics and hazards of respiratory syncytial virus and influenza virus infections among elderly people","volume":"24","author":"Yu","year":"2024","journal-title":"BMC Infect. Dis."},{"key":"B65","doi-asserted-by":"publisher","first-page":"e70029","DOI":"10.1111\/jch.70029","article-title":"Drug-related hypertension: a disproportionality analysis leveraging the FDA adverse event reporting system","volume":"27","author":"Zhu","year":"2025","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"key":"B66","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1002\/mus.21440","article-title":"Safety of influenza vaccination in patients with myasthenia gravis: a population-based study","volume":"40","author":"Zinman","year":"2009","journal-title":"Muscle Nerve"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1682119\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T05:24:15Z","timestamp":1760937855000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1682119\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,20]]},"references-count":66,"alternative-id":["10.3389\/fphar.2025.1682119"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1682119","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,20]]},"article-number":"1682119"}}